Cannabis is worth bothering about. by unknown
CANNABIS IN THE LAW
A controlled ‘Class B’ substance, cannabis
carries legal penalties for possession, supply,
and production. Between 2004–2009 cannabis
was reclassified as a ‘Class C’ substance,
meaning for a brief period of time it carried
lesser penalties for possession.
In 2009, the Association of Chief Police Officers
issued new guidance, advising officers to take
an escalating approach to the policing of
cannabis possession for personal use:
• A warning 
• A penalty notice for disorder (PND) 
• Arrest
This three-tiered approach was designed to be
“ethical and non-discriminatory”, but also
reinforce the “national message that cannabis
is harmful and remains illegal”.
For more on the classification of drugs,
including the difference between Class A, Class
B, and Class C drugs, visit this UK government
page.
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Cannabis is worth bothering with
Investigating the proposition that cannabis is worth bothering with, this hot topic looks at reports that stronger
cannabis on the market is increasing harms to users, prospects of recovery from disorders and dependence, and the
emerging response to synthetic forms of cannabis like ‘spice’.
In 1990s Britain a common reaction to allocating resources to
treating cannabis users was, ‘Why bother? We have more than
enough patients with problems with serious drugs like heroin.’
The typically calming use of the drug by adults was seen as
preferable to the main alternative – alcohol and its associated
violence and disorder. Calls for a treatment response were seen
as pathologising what in many societies is both normal and in
some ways desirable youth development: trying new experiences,
challenging conventions, and exposing the hypocrisy of alcohol-
drinking adults.
In 1997 the Independent on Sunday launched a campaign to
decriminalise cannabis, culminating in a mass ‘roll-up’, and
16,000-strong pro-cannabis march from Hyde Park to Trafalgar
Square. Its Editor Rosie Boycott wrote in the paper about her own
coming-of-age experience smoking cannabis, telling readers: 
“I Rolled my first joint on a hot June day in Hyde Park.
Summer of ’68. Just 17. Desperate to be grown-up. … My
first smoke, a mildly giggly intoxication, was wholly anti-
climatic. The soggy joint fell apart. I didn’t feel changed.
But that act turned me – literally – into an outlaw. I was on
the other side of the fence from the police – or the fuzz, as
we used to call them. So were a great many of my
generation.”
The campaign was explosive, but short-lived, apparently
subsiding when Boycott left to take up her role as Editor of the Daily Express. A decade later, the Independent issued
an apology for the campaign. ‘If only they had known then, what they knew now’, was the message of the article,
referring to the reportedly damaging impact of the more potent strains of cannabis and its links to “mental health
problems and psychosis for thousands of teenagers”.
Are stronger strains creating more problems?
There has been a long-standing, but controversial, association between cannabis strength and harm. Reading
newspaper articles on the subject, it wouldn’t be unusual to see a headline drawing a straight line between ‘super-
strength skunk’ and addiction, violence, deaths, or psychosis. In 2008, then Prime Minister Gordon Brown spoke in a
similar vein, telling a breakfast-television viewing audience: 
I have always been worried about cannabis, with this new skunk, this more lethal part of cannabis.
I don’t think that the previous studies took into account that so much of the cannabis on the streets is
now of a lethal quality and we really have got to send out a message to young people – this is not
acceptable.
Brown was warning of a dangerous new strain of cannabis on the market, that caused very severe harms to users –
contrasting starkly with the common perception of cannabis as a ‘low harm’ or ‘no harm’ drug.
The strength or potency of cannabis is determined by the amount of ‘THC’ it contains. THC produces the ‘high’
associated with cannabis, and another major component ‘CBD’ produces the sedative and anti-anxiety effects. As well
as potency, the relative amounts of THC and CBD are important for understanding the effects of cannabis – something
explored in a University College London study during the programme Drugs Live: Cannabis on Trial. The research
team compared two different types of cannabis: the first had high levels of THC (approx. 13%) but virtually no CBD;
and the second had a lower level of THC (approx. 6.5%) and substantial amounts of CBD (approx. 8%). They found
that CBD had a moderating or protective effect on some of the negative effects of THC, and that “many of the effects
that people enjoy are still present in low-potency varieties without some of the harms associated with the high-
potency varieties”.
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First-time treatment entrants in the
European Union by primary drug, 2006–12
At least in the US over the last two decades (between 1995–2014), potency has increased from around 4% to 12%,
and the protective CBD content of cannabis has decreased, from around 28% to less than 15%, significantly affecting
the ratio of THC to CBD, and with it, the nature and strength of the psychoactive effect of cannabis.
Until the 1990s, herbal cannabis sold in the UK was predominantly imported from the Caribbean, West Africa, and
Asia. After this time, it was increasingly produced in the UK, being grown indoors using intensive means (artificial
lighting, heating, and control of day-length). A study funded by the Home Office analysed samples of cannabis
confiscated by 23 police forces in England and Wales in 2008, and found that over 97% of herbal cannabis had been
grown by intensive methods; its average potency of 16% compared with just 8% for traditional imported herbal
cannabis. This matched other reports of home-grown cannabis being consistently (around 2–3 times) stronger than
imported herbal cannabis and cannabis resin.
In 2015, observing a decrease in the use of cannabis in England and Wales, but parallel increase in demand for
treatment, a UK study examined whether the trend could be explained by an increase in the availability of higher-
potency cannabis. Over 2500 adults were surveyed about their use of different types of cannabis, severity of
dependence, and cannabis-related concerns. The researchers found that higher potency cannabis was associated with
a greater severity of dependence, especially in young people, and was rated by participants as causing more memory
impairment and paranoia than lower potency types. However at the same time, it was reported to produce the best
‘high’, and to be the preferred type.
By definition cannabis is a psychoactive substance, which means it can change people’s perceptions, mood, and
behaviour. Higher potency cannabis contains more of the psychoactive component, so it makes sense that higher
potency cannabis could increase the risk of temporary or longer-term (adverse) problems with perceptions, mood, and
behaviour. However, there is a particular concern that cannabis use could be linked to ‘psychosis’, a term describing a
mental illness where a person perceives or interprets reality in a very different way to those around them, which can
include hallucinations or delusions.
Whether cannabis causes psychosis, precipitates an existing predisposition, aggravates an existing condition, or has
no impact at all on psychotic symptoms, has for decades been hotly contested. With our focus on evaluations of
interventions, Drug and Alcohol Findings is in no position to pronounce on this issue, nor on the possibility that the
drug might sometimes improve mental health, but some examples of research informing this debate are included
below.
A 2009 UK study examined whether daily use of high-potency cannabis was linked to an elevated risk of psychosis,
comparing 280 patients in London presenting with a first episode of psychosis with a healthy control group. The
patients were found to be more likely to smoke cannabis on a daily basis than the control group, and to have smoked
for more than five years. Among those who used cannabis, 78% of the patients who had experienced psychosis used
higher-potency cannabis, compared with 37% of those in the control group. The findings indicated that the risk of
psychosis was indeed greater among the people who were using high potency cannabis on a frequent basis, but
couldn’t show that the cannabis use caused the psychosis, or even that the cannabis use made the group more
susceptible to psychosis. The wider literature on mental health and substance use would suggest that the association
is more complex than this.
A recently published paper from the University of York has demonstrated the complications of attributing any
association between cannabis use and psychosis to a causal effect of cannabis use rather than other factors or a
reverse causal effect. A calculation based on data from England and Wales helped to put this into perspective,
indicating that even if cannabis did cause psychosis more than 20,000 people would need to be stopped using
cannabis to prevent just one case of psychosis.
The apparent steady increase in cannabis potency in the UK since the 1990s is important context for further research.
Where higher potency cannabis is increasingly becoming the norm, and is the preference for cannabis users, it would
be relevant to generate more evidence of the health-related problems with high potency cannabis, and the treatment
and harm reduction solutions based around these health-related problems.
Cannabis accounts for half of all new drug treatment patients
The most widely used illegal drug in Europe, many seemingly enjoy
cannabis without it leading to any significant negative social or health
effects. However, numbers entering treatment for cannabis use
problems have been on the rise (both in the UK, and the rest of
Europe), while heroin treatment numbers have fallen  chart. According
to Public Health England, this is not because more people are using
cannabis, but perhaps because services relieved of some of the recent
pressure of opiate user numbers are giving more priority to cannabis,
because they are making themselves more amenable to cannabis users,
and because of emerging issues with stronger strains of the drug.
Whatever the causes, across the UK figures submitted to the European
drug misuse monitoring centre show that the proportion of patients
starting treatment for drug problems who did so primarily due to their
cannabis use rose steadily from 11% in 2003/04 to 22% in 2011/12.
With the caveat that data from 2013 onwards is not directly comparable
due to changes in methodology, in 2014 and 2015 the proportion of
patients who entered treatment primarily because of a cannabis issue
hovered above previous years at 26% (25,278 and 26,295
respectively). Among first ever treatment presentations, the increase
from 2003/04 was more pronounced, from 19% to 37%. By 2013, cannabis use had become the main prompt for half
the patients who sought treatment for the first time (at 49%), and stayed relatively constant at 47% in 2014, and
48% in 2015.
Showing that more users was not the reason for more starting treatment, over about the same period, in England and
Wales the proportion of 16–59-year-olds who in a survey said they had used cannabis in the past year fell from about
11% to 7% in 2013/14, then stayed at that level in 2014/15 and 2015/16.
The treatment figures largely reflect trends in England, where in 2013/14 the number of patients starting treatment
with cannabis use problems had risen to 30,422, 21% of all treatment starters, up from 23,018 and 19% in 2005/06.
Subsequently the number dropped to 27,965 in 2015/16, still around a fifth of all treatment starters. Among the total
treatment population – starting or continuing in treatment – cannabis numbers rose from 40,240 in 2005/06 to peak
at 64,407 in 2013/14 before falling back to 59,918 in 2015/16; corresponding proportions again hovered around a
fifth.
As a primary problem substance among under-18s cannabis dominated, accounting for three-quarters of all patients
in treatment in 2015/16 and in numbers, 12,863. The dominance of cannabis increased from 2008/09 as numbers
primarily in treatment for drinking problems fell.
‘All treatments appear to work’
According to the two main diagnostic manuals used in Europe and the USA, problem cannabis use can develop into a
cannabis use disorder or cannabis dependence, identifiable by a cluster of symptoms including: loss of control;
inability to cut down or stop; preoccupation with use; neglecting activities unrelated to use; continued use despite
experiencing problems; and the development of tolerance and withdrawal.
This level of clinical appreciation for cannabis use problems didn’t exist when researcher and writer William L. White
entered the addictions field half a century ago: 
“When I first entered the rising addiction treatment system in the United States nearly half a century ago,
there existed no clinical concept of cannabis dependence and thus no concept of recovery from this
condition. In early treatment settings, cannabis was not consider[ed] a “real” drug, the idea of cannabis
addiction was scoffed at as remnants of “Reefer Madness,” and casual cannabis use was not uncommon
among early staff working in addiction treatment programs of the 1960s.
Many in the field remain sceptical of the idea of cannabis dependence, specifically whether problem users at the
severe end experience physiological withdrawal. However, reviewing what they believe is mounting evidence, these
authors suggest there can be confidence in the existence of a “true withdrawal syndrome” – albeit one that differs
qualitatively from the “significant medical or psychiatric problems as observed in some cases of opioid, alcohol, or
benzodiazepine withdrawals”. In the case of cannabis, the main symptoms are primarily emotional and behavioural,
although appetite change, weight loss, and some physical discomfort are reported. A brief review aimed at
practitioners in UK primary care provides guidance on how to manage symptoms of withdrawal among patients trying
to stop or reduce their cannabis use.
Research has come a long way, says William L. White, with now “clear data supporting the dependency producing
properties of cannabis, a clear conceptualization of cannabis use disorders (CUD) and cannabis dependence (CD)”, but
until recently, very little evidence about the prospects of long-term recovery. Yet, key papers – found here and here –
indicate that: 
• Full remission from cannabis use disorders is not only possible, but probable. 
• Stable remission takes time – an average of 33 months. 
• Abstinence may not be initially realistic for heavy cannabis users – but those in remission are usually able to reduce
the intensity of their use and its consequences.
At least in the United States, it seems dependence is more quickly overcome from cannabis than the main legal drugs.
A survey of the US general adult population found that within a year of first becoming dependent, 3% each of smokers
and drinkers were in remission and remained so until they were surveyed. For cannabis the figure was nearly 5% and
for cocaine, nearly 9%. After ten years the proportions in remission had risen to 18% for nicotine, 37% for alcohol,
66% for cannabis and 76% for cocaine. About 26 years after first becoming dependent, half the people at some time
dependent on nicotine were in remission, a milestone reached for alcohol after 14 years, for cannabis six years, and
for cocaine, five.
Many people experience
cannabis as enjoyable and
trouble free … some people
require help to reduce or stop
Specialised treatment programmes for cannabis
users in European countries
Generally for people with cannabis use problems, the European
Monitoring Centre for Drugs and Drug Addiction concluded in 2015, and
before that in 2008, that “all treatments appear to work”. For adults,
effective treatments include motivational interviewing, motivational
enhancement therapy and cognitive-behavioural therapy, and for
younger people, family-based therapies seem most beneficial. Less
important than the type of treatment is the treatment context and the
individual’s determination to overcome their problems through
treatment. And there is “no firm basis for a conclusion” that cannabis-
specific interventions (designed around the risks and harms associated
with cannabis) are more effective than general substance use treatment
tailored to the individual needs of the cannabis user seeking treatment 
chart.
In some studies brief interventions have been found to work just as well
as more intensive treatment, but when the patients are heavily
dependent, and the most difficult cases are not filtered out by the
research, longer and more individualised therapies can have the
advantage.
When the World Health Organization trialled its ASSIST substance use
screening and brief advice programme in Australia, India, the United
States, and Brazil, just over half the identified patients (all had to be at moderate risk of harm but probably not
dependent) were primarily problem cannabis users. Among these, risk reduction in relation to this drug was
significantly greater among patients allocated to a brief advice session than among those placed on a three-month
waiting list for advice. In each country too, risk reduction was greater among intervention patients, except for the
USA, where the order was reversed. Suggesting that severity of use was not a barrier to reacting well to brief
intervention, only patients at the higher end of the moderate risk spectrum further reduced their cannabis use/risk
scores following intervention. The ASSIST study was confined to adults, but young people in secondary schools in the
USA whose problem substance use focused mainly on cannabis also reacted well to brief advice.
The relative persistence of opiate use problems versus the transitory nature of those primarily related to cannabis
seemed reflected in an analysis of treatment entrants in England from 1 April 2005 to the end of 2013/14, the last
time this particular analysis was published. At the end of this period just 7% of primary cannabis users were still in or
back in treatment compared to the 30% overall figure and 36% for primary opiate users. The figure peaked at 43%
for users of opiates and crack. Over half – 53% – of primary cannabis users had left treatment as planned, apparently
having overcome their cannabis problems, compared to 27% of primary opiate users and just 20% with dual opiates
and crack use problems. Another 40% of cannabis users had left treatment in an unplanned manner, a slightly higher
proportion than among opiate users. The figures tell a tale of relatively high level of success which enables cannabis
users to leave treatment, though even in the absence of recorded success, few stay long-term.
However, the forms patients in England complete with their keyworkers while in treatment seem to tell a different
story. Compared to how they started treatment, around six months later 45% of primary cannabis users were
assessed as using just as often (including a few using more), compared to 30% of opiate users and 42% whose main
problem drugs were both opiates and crack, suggesting more rapid and/or more complete remission for opiate users
than for cannabis users. One interpretation is that the widespread use of substitute drugs like methadone more
reliably reduced the illegal opiate use of opiate users and also helped retain them in treatment, while cannabis users
tended quickly to leave treatment, having done well or not. However, these figures relate only to patients who
completed the forms at their six-month review, which in practice could have happened anywhere from about one to
six months after their assessment for treatment. What proportion of primary cannabis users were still in treatment at
that point and available to complete the forms is not clear, but they may have been the patients whose problems were
deep seated enough to require extended treatment.
Enjoyable and trouble-free for many, but not without harms
Harm reduction – the “set of practical strategies and ideas aimed at reducing negative consequences associated with
drug use” – is mostly associated with ‘harder’ drugs like heroin, for which blood-borne viruses and drug-related deaths
are clear and severe risks. Yet while “many people experience cannabis as enjoyable and trouble free”, there are also
varying degrees of harm with this drug depending on the characteristics of the person using, the type of the cannabis,
and the way they consume it.
Many formal cannabis harm reduction programmes borrow from the fields of alcohol and tobacco. Advice includes: 
• safer modes of administration (eg, on the use of vaporisers, on rolling safer joints, on less risky modes of inhaling) 
• skills to prevent confrontation with those who disapprove of use 
• encouraging users to moderate their use 
• discouraging mixing cannabis with other drugs 
• drug driving prevention and controls 
• reducing third-party exposure to second-hand smoke 
• education about spotting signs of problematic use 
• self-screening for problematic use
In some parts of the UK, National Health Service tobacco smoking cessation services incorporated cannabis into their
interventions with adults; and Health Scotland, also addressing the risks of tobacco and cannabis smoking, published
a booklet for young people titled Fags ‘n’ Hash: the essential guide to cutting down the risks of using tobacco and
cannabis.
Vaporising or swallowing cannabis offers a way to avoid respiratory risks, but only a minority of cannabis do this, most
choosing to smoke cannabis joints (or cannabis and tobacco joints). While not all will know about the different health
risks, cannabis users may choose against safer consumption methods anyway for a range of reasons (including their
own thoughts about safe use): 
• Users may find it easier to control the effects (eg, severity, length of effect) of cannabis when inhaling in the form of
‘SPICE’ AND OTHER
SYNTHETICS
Cannabis contains two key components: 
• ‘THC’ (tetrahydrocannabinol), which produces
the ‘high’ 
• ‘CBD’ (cannabidiol), which produces the
sedative and anti-anxiety effects
Synthetic forms of cannabis contain chemicals
that aim to copy the effects of ‘THC’ in
cannabis. But the effects of synthetic cannabis
can be quite different (and often stronger):
firstly, because synthetic production makes it
easier to manipulate the amount of the THC-
like chemical; and secondly, because of the
absence of the moderating equivalent of ‘CBD’.
a joint or spliff 
• Preparing and sharing joints can be an enjoyable part of the routine, or part of a person’s social activities 
• Alternative methods of smoking (eg, bongs and vaporisers) may be inconvenient to use, or expensive to buy
Most harm reduction advice is delivered informally long before users come into contact with drugs professionals – for
example through cannabis magazines, websites, and headshops – highlighting the importance of official sources
engaging with non-official sources to promote the delivery of accurate, evidence-based harm reduction messages.
A new high
In May 2016 the Psychoactive Substances Act placed a ‘blanket ban’
on new psychoactive substances (previously known as ‘legal highs’),
including synthetic cannabinoids (synthetic forms of cannabis).
Prior to this, in 2014, there had been 163 reported deaths from new
psychoactive substances in the UK, and 204 the year after. The
average age was around 28, younger than the average age for other
drug misuse deaths of around 38. The fact that these psychoactive
substances – which produced similar effects to illicit drugs like
cannabis, cocaine, and ecstasy – could be bought so easily online or
on the high street, appeared inconsistent; and each fatality prompted
“an outcry for something to be done to prevent further tragedies”.
This was the context (and arguably the political trigger) for the
introduction of the Psychoactive Substances Act. While possession of
a psychoactive substance as such wasn’t criminalised;, production,
supply, offer to supply, possession with intent to supply, import or
export were – with a maximum penalty of seven years’ imprisonment.
Just seven months after the Act came into effect, the Home Office labelled it a success, with a press release stating
that nearly 500 people had been arrested, 332 shops around the UK had been stopped from selling the substances,
and four people had been sent to prison. But did the Psychoactive Substances Act have the presumably desired effect
of limiting access to psychoactive substances (and reducing deaths), or did it just push the drugs the way of dealers?
It is perhaps too early to tell, but former chair of the Advisory Council on the Misuse of Drugs Professor Nutt had
warned before the Act came into effect that the ‘blanket ban’ would make it harder (not easier) to control drugs. And
while Chief executive of DrugWise Harry Shapiro had said the new law would make new psychoactive substances
harder to obtain, he also agreed that sale of the drugs would not cease, but merely be diverted to the illicit market:
“The same people selling heroin and crack will simply add this to their repertoire.”
The paper “From niche to stigma” examined the changing face of the new psychoactive substance user between 2009
and 2016, focusing on people using the synthetic cannabis known as ‘spice’. It looked at the transition of (then) ‘legal
highs’ from an “experimental and recreational” scene associated with a “niche middle class demographic”, to “those
with degrees of stigma”, especially homeless, prison, and socially vulnerable youth populations (including looked after
children, those involved in or at risk of offending, and those excluded or at risk of exclusion from mainstream
education). In 2014, the DrugScope Street Drug Survey also observed a problem among these particular groups,
recording a “rapid rise in the use of synthetic cannabinoids such as Black Mamba and Exodus Damnation by opiate
users, the street homeless, socially excluded teenagers and by people in prison”.
Some synthetics are purposely designed to resemble herbal
cannabis, and can be consumed in the same ways (eg, smoked or
inhaled). The names also often have deliberate cannabis
connotations. The risk of this is that people wishing to take
cannabis may be initially unaware that they have been sold the
synthetic form, or may believe from the look of it that it will
produce similar sought-after effects. The greater intensity of
synthetic cannabis at lower dose levels (  box) ensures that it has
an appeal in terms of potency and affordability, but may put
those with fewer resources at greater harm.
In 2014, the prison inspectorate for England and Wales raised
concerns about the rise in the use of psychoactive substances in
prisons, in particular synthetic cannabis. A study set in an English
adult male prison found that the nature of the market was posing
significant challenges to the management of offenders. There, the
primary motivation for consumption was being able to take a
substance without it being detected. Given this motivation, and
the greater likelihood of harms from synthetic versus natural
cannabis, the researchers concluded that it was imperative for mandatory drug-testing policies to be revised, and
instead rooted in harm reduction – something which would also apply to people on probation subject to mandatory
drug-testing.
Cannabis throws up a range of issues rather different from those associated with the drugs treatment in the UK has
normally focused on. If current trends continue, understanding the findings will become yet more important to British
treatment services.
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